Industry News
Final patient treated in PolyNovo BTM trial
Plastic surgeons have completed treatment for the last of 10 patients enrolled in a trial of PolyNovo’s NovoSorb BTM in free-flap donor site repair surgery. [ + ]
Bionomics begins safety program for cancer antibody
Bionomics (ASX:BNO) has launched IND-enabling pharmacology and toxicology studies for BNC101, its anticancer antibody candidate. [ + ]
Register now for Australia Biotech Invest
You can register now to attend Australia Biotech Invest where you will hear world-leading biotech innovators and Australia’s investment community discuss the future of biotech in the Antipodes. [ + ]
Opportunities for Australian biotechs in Switzerland
Geneva-based Campus Biotech is open to Australian biotech companies interested in establishing offices of R&D facilities in Europe. [ + ]
Invion opens phase II trial for chronic bronchitis
Recruitment has begun for Invion’s phase II trial that aims to repurpose nadolol as a treatment for smoking cessation. [ + ]
Phylogica and Cubist team up to evaluate antimicrobial Phylomers
Peptide drug discovery company Phylogica (ASX: PYC) is collaborating with US-based Cubist Pharmaceuticals (NASDAQ: CBST) to evaluate several of its antimicrobial Phylomers in models of multidrug-resistant bacterial infections. [ + ]
FDA permits marketing of TB bacteria and antibiotic-resistance test
The US Food and Drug Administration (FDA) has authorised the marketing of the Xpert MTB/RIF assay, manufactured by Cepheid. This is the first FDA-reviewed test that can rapidly detect the bacteria that cause tuberculosis (TB) and determine if the bacteria contain genetic markers that make them resistant to rifampin, an important antibiotic for the treatment of TB. [ + ]
Biofuel production from Australian algae
Native species of algae have been identified as potential candidates for the development of cheap, efficient and commercially viable alternative fuels. [ + ]
Partnership to prepare for the next pandemic
A $20 million research partnership between Australia, Singapore and the US aims to prepare the world for its next pandemic. [ + ]
HPV increases risk of oesophageal cancer
The human papillomavirus has been linked to yet another malignancy - cancer of the oesophagus. [ + ]
Registrations open for Australia’s premier biotech investment and capital raising event
AusBiotech and Beacon Events have joined forces to launch Australia’s premier event for biotech investment and capital raising - Australia Biotech Invest. [ + ]
Patrys doses third group in multiple myeloma trial
Patrys (ASX:PAB) has completed initial treatment for the third of four groups of patients in a phase I/IIa trial of the company’s anticancer antibody, PAT-SM6, in multiple myeloma. [ + ]
QRxPharma collaborates with Aesica
Melbourne-based biopharmaceutical company QRxPharma (ASX: QRX) has announced a collaboration agreement with Aesica Pharmaceuticals subsidiary Aesica Formulation Development. [ + ]
Qiagen and Exosome Diagnostics partner to create biofluid sample preparation kits
Qiagen and Exosome Diagnostics have announced a partnership to develop and commercialise high-performance kits for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles. [ + ]
Phosphagenics releases results of investigation
An independent investigation into irregularities in Phosphagenics’ accounts has revealed that $5.7 million has been misappropriated from the company over the past eight years. [ + ]
